GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (NAS:TLRY) » Definitions » Retained Earnings

TLRY (Tilray Brands) Retained Earnings : $-2,699.7 Mil (As of Aug. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Tilray Brands Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Tilray Brands's retained earnings for the quarter that ended in Aug. 2024 was $-2,699.7 Mil.

Tilray Brands's quarterly retained earnings declined from Feb. 2024 ($-2,628.7 Mil) to May. 2024 ($-2,660.5 Mil) and declined from May. 2024 ($-2,660.5 Mil) to Aug. 2024 ($-2,699.7 Mil).

Tilray Brands's annual retained earnings declined from May. 2022 ($-962.9 Mil) to May. 2023 ($-2,415.5 Mil) and declined from May. 2023 ($-2,415.5 Mil) to May. 2024 ($-2,660.5 Mil).


Tilray Brands Retained Earnings Historical Data

The historical data trend for Tilray Brands's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands Retained Earnings Chart

Tilray Brands Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -113.35 -486.05 -962.85 -2,415.51 -2,660.49

Tilray Brands Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,487.03 -2,536.04 -2,628.74 -2,660.49 -2,699.65

Tilray Brands Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Tilray Brands  (NAS:TLRY) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Tilray Brands Business Description

Traded in Other Exchanges
Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
Executives
Carl A Merton officer: Chief Financial Officer C/O TILRAY, INC., 745 FIFTH AVENUE, SUITE 1602, NEW YORK NY 10151
Denise M Faltischek officer: Chief Strategy Officer C/O THE HAIN CELESTIAL GROUP, INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Mitchell Gendel officer: Global General Counsel EMERALD HOLDING, INC., 100 BROADWAY, 14TH FLOOR, NEW YORK NY 10005
Irwin D Simon director, officer: President & CEO C/O THE HAIN CELESTIAL GROUP INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Brendan Kennedy director 1920 EASTLAKE AVENUE E., SEATTLE WA 98105
James R. Meiers officer: Head of Canada C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David G. Hopkinson director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Thomas P. Looney director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Johann Michael Herhalt director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Jodi L. Butts director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David F Clanachan director TIM HORTONS INC., 874 SINCLAIR ROAD, OAKVILLE A6 L6K 2Y1
Renah Persofsky director 55 PRINCE ARTHUR AVENUE, #604, TORONTO A6 M5R 1B3
Jon Edward Levin officer: Chief Operating Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Michael C. Kruteck officer: Chief Financial Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Rebekah Dopp director 444 LENOX AVENUE, SOUTH ORANGE NJ 07079